Sheffield cancer consultant named president of European group for rare pregnancy tumours

A consultant medical oncologist from Sheffield Teaching Hospitals NHS Foundation Trust has become the new president of the European Organisation for Treatment of Trophoblastic Diseases (EOTTD). Consultant medical oncologist at Weston Park Cancer Centre Professor Matt Winter will hold the role for two years.

He joined the cancer centre in 2011 as a consultant and has dedicated his career to treating patients with breast cancer and gestational trophoblastic disease, a rare group of conditions where tumours grow from the placental tissue formed during pregnancy.

In 2022, he became director of the Sheffield Gestational Trophoblastic Centre based at Weston Park, one of two specialist national centres commissioned by NHS England to treat women with these tumours.

Prior to the opening of the national centres in 1973, nearly all patients died from the condition. However, over the past 50 years, outcomes have transformed, with the disease now being up to 95 per cent curable. As president of the EOTTD, Professor Winter will play a leading role in helping to deliver the organisation’s aims of optimising diagnosis, treatment, follow-up and research in gestational trophoblastic disease. He said: “In the UK, we are so fortunate to have a national gestational trophoblastic disease service for screening and treatment. Most other European countries do not have this and in such a rare disease, centralisation of care is essential to achieve the best outcomes for patients.”

Read this report on page 8 of the September 2025 issue of RAD Magazine.

The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.